{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470637387
| IUPAC_name = 1-methoxy- 3-[4-(2-methoxy- 2-phenylethyl)piperazin- 1-yl]- 1-phenylpropan- 2-ol
| image = zipeprol.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|zipeprol}}
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled, S2, S3, S4, S5, S6, S7, S8, S9 -->
| legal_DE = Anlage II
| legal_CA = Schedule III
| legal_UK = <!-- GSL, P, POM, CD, Class A, B, C -->
| legal_US = Schedule I <!-- OTC, Rx-only, Schedule I, II, III, IV, V -->
| legal_status =  Schedule II international{{how|date=February 2017}}
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 34758-83-3
| ATC_prefix = R05
| ATC_suffix = DB15
| PubChem = 36910
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 33868
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G5MUV8139H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07390

<!--Chemical data-->
| C=23 | H=32 | N=2 | O=3 
| molecular_weight = 384.512 g/mol
| smiles = OC(CN1CCN(CC1)CC(OC)c2ccccc2)C(OC)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H32N2O3/c1-27-22(19-9-5-3-6-10-19)18-25-15-13-24(14-16-25)17-21(26)23(28-2)20-11-7-4-8-12-20/h3-12,21-23,26H,13-18H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VSTNNAYSCJQCQI-UHFFFAOYSA-N
}}

'''Zipeprol''' is a centrally acting [[cough suppressant]] developed in France in the 1970s.<ref>Patent {{cite patent| country=US | number=3718650 | pridate= 1970-03-02 | gdate=1973-02-27 | inventor=Mauvernay, RY | title = New Derivatives of Substituted Piperazines}}</ref> It is not an [[morphinan]] derivative (in contrast to [[codeine]] and [[dextromethorphan]]). Zipeprol acts as a local anaesthetic and has [[mucolytic]], [[antihistamine]] and [[anticholinergic]] properties.<ref>{{Cite journal 
| last1 = Rispat | first1 = G. 
| last2 = Burgi | first2 = H. 
| last3 = Cosnier | first3 = D. 
| last4 = Duchêne-Marullaz | first4 = P. 
| last5 = Streichenberger | first5 = G. 
| title = General pharmacological properties of a new non-opiate antitussive: Zipeprol (3024 CERM). I. Action on respiratory function and acute toxicity 
| journal = Arzneimittel-Forschung 
| volume = 26 
| issue = 4 
| pages = 523–530 
| year = 1976 
| pmid = 8057
}}</ref>It is sold with several brand names such as '''Zinolta''' and '''Respilene'''. It is not available in the United States or Canada and has been discontinued in Europe. It is still available in some countries in Asia and South America.

Zipeprol has been misused in Korea, mainly for the hallucinations it produces. Such use has become an issue due to the seizures and various neurological side effects it causes at high dosages.<ref>{{Cite journal 
| last1 = Chung | first1 = H. 
| last2 = Park | first2 = M. 
| last3 = Hahn | first3 = E. 
| last4 = Choi | first4 = H. 
| last5 = Choi | first5 = H. 
| last6 = Lim | first6 = M. 
| doi = 10.1196/annals.1316.056 
| title = Recent Trends of Drug Abuse and Drug-Associated Deaths in Korea 
| journal = Annals of the New York Academy of Sciences 
| volume = 1025 
| pages = 458–464 
| year = 2004 
| pmid = 15542749 
| pmc = 
}}</ref>

==References==
{{reflist}}


{{Cough and cold preparations}}
{{Piperazines}}

[[Category:Antitussives]]
[[Category:Piperazines]]
[[Category:Ethers]]
[[Category:Alcohols]]

{{respiratory-system-drug-stub}}